🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s SNY Holdings & Trades

First Buy
Q2 2013
Duration Held
51 Quarters
Largest Add
Q2 2013
+12.81 M Shares
Current Position
12.14 M Shares
$588.33 M Value

Ken Fisher's SNY Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 12.14 M shares of Sanofi (SNY) worth $588.33 M, representing 0.20% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.

Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in SNY, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2023, adding 1.99 M shares. Largest reduction occurred in Q3 2022, reducing 3.63 M shares.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Sanofi (SNY) Holding Value Over Time

Track share changes against reported price movement

Quarterly Sanofi (SNY) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -438,131 Reduce 3.48% 12.14 M $48.46
Q3 2025 -556,620 Reduce 4.24% 12.58 M $47.20
Q2 2025 -430,963 Reduce 3.18% 13.14 M $48.31
Q1 2025 +1.06 M Add 8.43% 13.57 M $55.46
Q4 2024 -848,083 Reduce 6.35% 12.51 M $48.23
Q3 2024 -239,392 Reduce 1.76% 13.36 M $57.63
Q2 2024 -349,081 Reduce 2.50% 13.6 M $48.52
Q1 2024 -342,808 Reduce 2.40% 13.95 M $48.60
Q4 2023 -652,327 Reduce 4.37% 14.29 M $49.73
Q3 2023 +1.99 M Add 15.33% 14.94 M $53.64
Q2 2023 -394,643 Reduce 2.96% 12.96 M $53.90
Q1 2023 -430,041 Reduce 3.12% 13.35 M $54.42
Q4 2022 -204,875 Reduce 1.46% 13.78 M $48.43
Q3 2022 -3.63 M Reduce 20.59% 13.99 M $38.02
Q2 2022 -320,069 Reduce 1.78% 17.61 M $50.03
Q1 2022 -48,854 Reduce 0.27% 17.93 M $51.34
Q4 2021 +75,166 Add 0.42% 17.98 M $50.10
Q3 2021 +21,337 Add 0.12% 17.91 M $48.21
Q2 2021 -247,533 Reduce 1.37% 17.89 M $52.66
Q1 2021 -82,259 Reduce 0.45% 18.13 M $49.46
Q4 2020 -409,356 Reduce 2.20% 18.21 M $48.59
Q3 2020 +468,585 Add 2.58% 18.62 M $50.17
Q2 2020 +493,628 Add 2.79% 18.16 M $51.05
Q1 2020 +114,682 Add 0.65% 17.66 M $43.72
Q4 2019 +170,342 Add 0.98% 17.55 M $50.20
Q3 2019 +508,580 Add 3.01% 17.38 M $46.33
Q2 2019 +367,961 Add 2.23% 16.87 M $43.27
Q1 2019 +459,410 Add 2.86% 16.5 M $44.28
Q4 2018 +414,369 Add 2.65% 16.04 M $43.41
Q3 2018 +4,121 Add 0.03% 15.63 M $44.67
Q2 2018 +549,110 Add 3.64% 15.62 M $40.01
Q1 2018 +572,694 Add 3.95% 15.07 M $40.08
Q4 2017 +418,501 Add 2.97% 14.5 M $43.00
Q3 2017 +443,799 Add 3.25% 14.08 M $49.79
Q2 2017 +1.02 M Add 8.11% 13.64 M $47.91
Q1 2017 +123,470 Add 0.99% 12.62 M $45.25
Q4 2016 +48,838 Add 0.39% 12.49 M $40.44
Q3 2016 -1.19 M Reduce 8.76% 12.44 M $38.19
Q2 2016 +91,233 Add 0.67% 13.64 M $41.42
Q1 2016 +130,730 Add 0.97% 13.55 M $43.77
Q4 2015 +120,254 Add 0.90% 13.42 M $42.65
Q3 2015 +49,373 Add 0.37% 13.3 M $47.47
Q2 2015 +188,498 Add 1.44% 13.25 M $49.53
Q1 2015 -26,938 Reduce 0.21% 13.06 M $49.44
Q4 2014 -60,614 Reduce 0.46% 13.09 M $45.61
Q3 2014 +66,072 Add 0.51% 13.15 M $56.43
Q2 2014 +153,173 Add 1.18% 13.08 M $53.17
Q1 2014 +116,737 Add 0.91% 12.93 M $52.28
Q4 2013 -18,344 Reduce 0.14% 12.81 M $53.63
Q3 2013 +19,148 Add 0.15% 12.83 M $50.63
Q2 2013 +12.81 M Add 0.00% 12.81 M $51.51

Ken Fisher's Sanofi Investment FAQs

Ken Fisher first purchased Sanofi (SNY) in Q2 2013, acquiring 12,808,861 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Sanofi (SNY) for 51 quarters since Q2 2013.

Ken Fisher's largest addition to Sanofi (SNY) was in Q2 2013, adding 12,808,861 shares worth $659.78 M.

According to the latest 13F filing for Q4 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 12,140,615 shares of Sanofi (SNY), valued at approximately $588.33 M.

As of the Q4 2025 filing, Sanofi (SNY) represents approximately 0.20% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Sanofi (SNY) was 18,624,240 shares, as reported at the end of Q3 2020.